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Abstract
Background: Structured exercise training has been proposed as a useful adjunctive therapy for Crohn’s disease by
improving immune function and psychological health, reducing fatigue and promoting gains in muscle and bone
strength. However, the evidence for exercise in Crohn’s disease is sparse, with only a handful of small prospective
trials [1, 2], with methodological limitations, including the use of non-randomised and non-controlled study designs
and small sample sizes. Here, we describe the protocol for a study that aims to assess the feasibility and
acceptability of two common types of exercise training—high-intensity interval training (HIIT) and moderate-
intensity continuous training (MICT)—in adults with inactive or mildly active Crohn’s disease (CD).
Methods: This is a randomised, controlled, assessor-blinded, feasibility trial with three parallel groups. Forty-five
adults with inactive or mildly active Crohn’s disease will be randomly assigned 1:1:1 to HIIT, MICT or usual care
control. Participants in the HIIT and MICT groups will be invited to undertake three sessions of supervised exercise
each week for 12 consecutive weeks. HIIT sessions will consist of ten 1-min intervals of cycling exercise at 90% of
peak power output separated by 1 min of active recovery. MICT sessions will involve 30 min of continuous cycling
at 35% of peak power output. Participants will be assessed before randomisation and 13 and 26 weeks after
randomisation. Feasibility outcomes include rates of recruitment, retention and adherence. Interviews with
participants will explore the acceptability of the exercise programmes and study procedures. Clinical/health
outcomes include cardiorespiratory fitness, body mass index, resting blood pressure, markers of disease activity
(faecal calprotectin and Crohn’s Disease Activity Index) and activated T cell cytokine profiles. Study questionnaires
include the Inflammatory Bowel Disease Quality of Life Questionnaire, EQ-5D-5L, IBD Fatigue Scale, Hospital and
Anxiety Depression Scale, and International Physical Activity Questionnaire.
Discussion: This study will provide useful information on the feasibility and acceptability of supervised exercise
training in adults with inactive and mildly active Crohn’s disease and will inform the design of a subsequent,
adequately powered, multi-centre trial.
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Background
Crohn’s disease (CD) is a relapsing inflammatory disease,
affecting the gastrointestinal tract, which often presents
with abdominal pain, fever, bowel obstruction or diar-
rhoea. In 2012, there were reported to be at least
115,000 people in the UK with CD [3]. For people in
remission or with less active disease, treatment is largely
directed at preventing relapse and maintaining or im-
proving health-related quality of life [4].
Management options for CD include drug and/or
biologic therapy, nutrition and diet modification, surgery
and smoking cessation [4]. Physical exercise, whilst not
currently part of the recommended treatment pathway,
has been proposed as a potentially useful adjunctive
therapy for CD by improving immunological responses
and psychological health, reducing fatigue and pro-
moting gains in muscle and bone strength [3]. However,
the evidence base for exercise in CD is sparse, with only
a handful of relevant studies, many of which have
methodological limitations, including the use of non-
randomised and non-controlled study designs and small
sample sizes [3].
The effects of exercise training depend largely on the
type, intensity and volume of the exercise stimulus [5].
The most common model of exercise prescription in
other chronic diseases has been moderate-intensity
continuous training (MICT, e.g. 30 min of moderate-
intensity continuous endurance-type exercise such as
swimming, cycling or jogging thrice weekly). This is well
tolerated and has beneficial effects on many different
aspects of physical and mental health [6]. However, a
growing body of evidence indicates that shorter bouts of
intense intermittent exercise—so-called ‘high-intensity
interval training’ (HIIT, e.g. 1 min of hard exercise
followed by 1 min of easy exercise repeated ten time-
s)—can elicit similar physiological adaptations compared
to more lengthy continuous exercise [7]. There has only
been one published report investigating HIIT in people
with CD to date [8], which demonstrated a single session
of cycle-based HIIT was well tolerated and did not
significantly increase inflammatory biomarkers in a
group of 15 teenage patients. A greater understanding
of the acceptability of, and chronic adaptations to,
different types of exercise training is clearly warranted
for safe and effective exercise promotion strategies in
adults with CD.
We hypothesise that supervised exercise training will
be an effective means of improving health-related quality
of life, fatigue and physical and mental health in people
with inactive or mildly active CD. Before embarking on
an adequately powered randomised controlled trial to
test this hypothesis, we have planned a feasibility study
that will address several areas of uncertainty. For example,
fatigue and a perceived inability to manage exercise have
been cited as barriers to exercise in people with inflamma-
tory bowel disease [9]. This raises questions about how
easy it will be to recruit and retain participants in a super-
vised exercise training trial. The objectives of the present
feasibility study are the following:
1. To explore the acceptability, safety and potential
benefits of HIIT and MICT in people with inactive
and mildly active CD, relative to usual care.
2. To evaluate the feasibility of conducting a future
large-scale randomised controlled trial to assess the
clinical effectiveness of exercise training in people
with CD in terms of recruitment, retention,
adherence and acceptability.
3. To identify a primary outcome and estimate the
parameters required to inform sample size
calculation for an adequately powered randomised
controlled trial.
Methods
Study design
EXACT (Exercise for Adults with Crohn’s disease Trial)
is a multi-centre, three-arm, parallel-group, randomised
controlled feasibility trial. Following baseline assessment,
participants will be randomly assigned 1:1:1 to usual care
plus HIIT, usual care plus MICT or usual care alone.
Study assessments will be conducted at baseline and at
13 and 26 weeks after randomisation.
Study setting
Participants will be recruited from three National Health
Service (NHS) Hospital Trusts: Guy’s and St Thomas’
NHS Foundation Trust, Barts Health NHS Trust and
Hampshire Hospitals NHS Foundation Trust. The exer-
cise programmes will be delivered in the exercise science
facilities of the University of East London and the
University of Winchester. The study is sponsored by the
University of Hertfordshire.
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Eligibility criteria
Inclusion criteria
 Age 16–65 years.
 Clinical diagnosis of CD for at least 4 weeks before
the screening visit.
 Inactive (<150 on Crohn’s Disease Activity Index
[CDAI]) or mildly active (150–219 on CDAI) CD
assessed no greater than 4 weeks before the
screening visit.
 Faecal calprotectin <250 mcg/g recorded no greater
than 4 weeks before the screening visit.
 Stable medication for at least 4 weeks before the
screening visit.
 Willing and able to provide written informed
consent and complete the study questionnaires.
 Willing and able to travel to the research centre for
assessment visits and exercise sessions.
Exclusion criteria
 Absolute contraindications to exercise testing and
training as defined by the American College of
Sports Medicine [10].
 Coexistent serious autoimmune disease such as
rheumatoid arthritis or systemic sclerosis.
 Planned major surgery within the first 3 months
after randomisation.
 Pregnant
 Female planning pregnancy within the first
3 months after randomisation.
 Poor tolerability of venepuncture.
 Lack of adequate venous access for required blood
sampling.
 Current participation in >90 min/week of purposeful
exercise, such as jogging or swimming.
 Participation in another clinical trial for with
concurrent participation is deemed inappropriate.
Interventions
High-intensity interval training (HIIT)
Participants allocated to the HIIT group will be invited
to complete three sessions of HIIT each week for 12
consecutive weeks. It is anticipated that most sessions
will be completed within normal office hours (i.e. 0900
to 1700) on Monday, Wednesday and Friday each week;
however, early morning, evening and weekend sessions
will be offered to facilitate attendance of participants
who cannot attend on these days or times. The exercise
will be performed on a calibrated, stationary upright
cycle ergometer. Each session will begin with 5 min of
cycling at 15% of the peak power output (Wpeak)
recorded during the baseline cardiopulmonary exercise
test. The main body of each session will involve ten
1-min bouts of cycling at 90% of Wpeak, interspersed
with 1-min bouts of cycling at 15% of Wpeak [11].
The session will end with 3 min of cycling at 15% of
Wpeak. Similar protocols of HIIT have been shown to
be safe and effective for improving cardiorespiratory
fitness in various clinical and non-clinical populations
[12, 13]. Incremental cycle exercise testing, without
the analysis of expired gases and blood lactate re-
sponses, will be performed during the final sessions
of the fourth and eighth week of training (i.e. at ses-
sions 12 and 24 of 36) and will replace the normal
exercise training of those sessions. The peak power
output recorded during these tests will be used to
adjust the power output used within the training ses-
sions (i.e. the training will be progressed after 4 and
8 weeks according to changes in peak power output
assessed using incremental cycle exercise testing).
Each session will be supervised by a research assistant
who will have received specific training from the investi-
gators in how to deliver the exercise protocol. A max-
imum of four participants will be trained per session. A
specifically designed exercise session case report form
(CRF) will be completed for each exercise session. Prior
to exercise, and 10-min post-exercise, the participant’s
resting heart rate and blood pressure will be recorded
(Omron, M2, The Netherlands). Differential ratings for
breathlessness and leg exertion will be assessed using
Borg’s CR-10 scale [14] before exercise, immediately
post, and 10-min post-exercise. In addition, participants
will be asked to rate their breathlessness and leg exertion
at 2.5, 7.5, 42.5, 47.5, 92.5 and 97.5% of exercise com-
pleted. These time points were chosen to incorporate
both interval and recovery periods during the HIIT
protocol [15]. Participants’ heart rate will also be re-
corded using Polar heart rate monitors at 2.5, 42.5 and
92.5% of exercise completed. The one item Feeling Scale
(FS; [16]) will be used to measure general affective
valence (i.e. pleasure and displeasure). Participants will
be prompted at the beginning of each exercise visit with
the following instructions: ‘While participating in exer-
cise, it is common to experience changes in mood. Some
individuals find exercise pleasurable, whereas others find
it to be unpleasant. Additionally, feeling may fluctuate
across time. That is, one might feel good and bad a
number of times during exercise. When asked, please
tell me how you feel at that current moment using the
scale below.’ The feeling scale is scored on an 11-point
bipolar scale ranging from −5 (very bad) to +5 (very
good). The FS will be administered pre-, immediately
post and 10-minutes post-exercise. To assess in-task
affect, the FS will be administered at 2.5, 42.5 and 92.5%
of exercise completed. The collection of such data will
permit a detailed quantification of the exercise interven-
tion. The research assistant will be required to email a
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copy of the anonymised exercise session CRF for
sessions 1, 13 and 25 to a member of the trial manage-
ment team so that they can confirm that the CRF and
sessions are being completed appropriately.
Overall enjoyment of the exercise programme will be
assessed during the week 13 assessment, using the vali-
dated multi-dimensional Physical Activity Enjoyment
Scale (PACES) [17]. This will typically be 3–7 days follow-
ing completion of the overall programme, allowing partici-
pants’ reflection and evaluation time. Participants in the
control group will not be required to complete this.
Moderate-intensity continuous training (MICT)
Participants allocated to the MICT group will be invited
to complete three cycle-based exercise sessions each week
for 12 weeks, with each session involving a warm-up and
cool-down of cycling at 15% of Wpeak. The main body of
each exercise session in this group involves 30 min cycling
at 35% of Wpeak. This programme has been selected
because it has been shown to elicit a similar energy
expenditure compared with the HIIT programme [11]. As
described for the HIIT group above, the training will be
progressed according to changes in peak power output re-
assessed after 4 and 8 weeks. Heart rate, perceived exer-
tion and general affective valence will be recorded at the
same relative time points as in the HIIT group.
Both exercise programmes will be delivered in addition
to usual care. Participants in both exercise groups will be
able to claim up to £10.90 per session for travel expenses.
After completing the 12-week intervention period, all
exercise group participants will receive an individualised
exercise programme that they can manage on their own.
The exercise prescription will largely reflect the content
of the supervised exercise programme; however, for
example, the mode of exercise may change if a cycle
ergometer cannot be easily accessed by the participant.
Usual care control group
This group will not receive any supervised exercise or be
given any specific recommendations regarding exercise.
However, once control participants have completed the
26-week assessment, they will be offered a one-to-one
exercise consultation via telephone with the research
assistant in which they will discuss the benefits of exercise
training, barriers and facilitators of exercise, exercise
guidelines and personal goals and action plans. The aim of
offering this consultation to control participants is to help
minimise the potential for resentful demoralisation that
may occur through being allocated to this group [18].
Outcome measures
Feasibility and acceptability outcomes
The main focus of this study is feasibility and acceptability
of procedures for recruitment, allocation, measurement,
retention and the intervention procedures. Recruitment
rates will be measured as rate of invited participants who
are eligible and consenting and will be reported in a
Consolidated Standards of Reporting Trials (CONSORT)
participant flowchart. Acceptability of allocation proce-
dures will be assessed by examining reasons for dropout
in discontinuing participants and comparing attrition rates
between the three study groups and between participants
who did and did not receive their preferred allocation
(assessed prior to randomisation). Suitability of measure-
ment procedures will be evaluated based on completion
rates and rates of missing data. Attrition rates will be
established as discontinuation of intervention and loss to
follow-up measurement for all groups. The acceptability
of the exercise programmes will be assessed using session
adherence rates, measures of exercise enjoyment (see the
Interventions section) and participant and provider feed-
back via telephone interviews conducted after the 26-
week follow-up visit. The participant interviews will last
up to 30 min and will cover perceived benefits and nega-
tive consequences from participating in the study, feed-
back regarding specific design features of the study
(including the exercise protocol and assessment proce-
dures) and perceptions of barriers and facilitators to inter-
vention participation. The safety of exercise training will
also be assessed by exploring rates of disease relapse at
13 weeks, reasons for dropout from the exercise pro-
grammes and the number and type of adverse events, both
CD specific and general, which occur in each group.
Behavioural and health-related outcomes
In addition to acceptability and feasibility, we will assess
the following outcome measures in all participants
before randomisation and 13 weeks after randomisation:
body mass, stature, waist circumference, blood pressure,
resting heart rate, cardiorespiratory fitness (ventilatory
threshold and peak oxygen uptake), disease status and
relapse (CDAI), intestinal inflammation (faecal calpro-
tectin) and blood markers of inflammation* (T lympho-
cyte subsets [Th1/Th2/Th17] and various cytokines
including IL-6, IL-10, TNF-α and C-reactive protein [via
2 × 1-mL blood samples drawn from non-fasted partici-
pants at each time point]). Relapse will be defined as an
increase in CDAI score of at least 100 points, to a level
greater than 150 [19]. Questionnaires will also be admin-
istered before and 13 and 26 weeks after randomisation,
including the Inflammatory Bowel Disease Quality of
Life Questionnaire (IBDQ) [20], EuroQol EQ-5D-5L
[21], IBD Fatigue Scale [22], Hospital and Anxiety De-
pression Scale (HADS) [23] and International Physical
Activity Questionnaire (IPAQ)—Short Form [24].
*NOTE: The blood markers of inflammation will also
be assessed after 6 weeks of exercise training in the par-
ticipants in the two exercise groups only. Here, venous
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blood will be collected at the start of the first session of
the 7th week of exercise training (i.e. before commen-
cing the 19th exercise session). This additional blood
assessment has been included to provide an indication
of the time course of changes in circulating inflamma-
tory markers with chronic exercise training.
The assessment of cardiorespiratory fitness will be
achieved by measuring ventilatory threshold and peak
oxygen uptake. Participants will undergo cardiopulmonary
exercise testing using an incremental protocol on an elec-
tronically braked cycle ergometer (Lode, Corival, The
Netherlands). After 2 min of unloaded cycling, the inten-
sity of exercise will be increased by 15–25 W min−1. The
target cadence will be 60–80 rev min−1. Participants will
be encouraged to continue cycling to volitional exhaus-
tion. Heart rate monitoring will be performed continu-
ously (Polar, S610i, Finland). Rating of perceived exertion
(RPE; Borg 6–20 scale [14]) will be recorded at the end of
every minute. The volume of oxygen consumed during
exercise was calculated from minute ventilation and
measured using a pneumotachometer and simultan-
eous breath-by-breath analysis of expired gas fractions
(Cosmed, K5, Italy). Gas analysers and flow probes will be
calibrated before each test. Oxygen consumption will be
expressed relative to body mass (mL∙kg−1∙min−1). Ventila-
tory threshold will be determined by an independent
exercise physiologist blinded to group allocation using the
v-slope and ventilatory equivalents methods [25].
Peak oxygen uptake will be calculated as the highest
consecutive 20-s period of oxygen uptake data in the
last minute before volitional exhaustion. For an exer-
cise test to be considered valid, at least two of the
following criteria must be satisfied: respiratory ex-
change ratio ≥1.1, RPE ≥17, heart rate ≥95% age-
predicted maximum (220 minus age), post-exercise
blood lactate ≥6.0 mM.
Participant timeline
Figure 1 illustrates the process of enrolling participants
into the study, the interventions being compared, and
timing of assessments and hospital visits for the partici-
pants in the trial.
Sample size
As this is a feasibility study, no formal sample size calcu-
lation was performed [26]. Instead, this study follows
sample size recommendations for pilot randomised
controlled trials [27] and aims to have at least 12 partici-
pants per study arm who provide full data. We aim to
recruit 15 participants to each group (i.e. total sample
size of 45) to allow up to 20% attrition, which is appro-
priate based on our exercise studies in other clinical
populations [28–30]. This number of participants is
deemed adequate to provide sufficient information on
key feasibility issues such as recruitment, retention and
acceptability of the exercise programmes.
Recruitment
Recruitment methods will include advertisements through
the local media and charity groups (e.g. Crohn’s and
Colitis UK), invitations to participants in previous studies
who have given their consent to be contacted regarding
future research projects, and liaisons with direct care
teams at recruiting NHS Hospital Trusts. For the lat-
ter of these methods, a member of the direct care
team will identify potentially eligible patients via re-
view of medical notes ahead of clinics and database
screening of clinic letters.
Potentially eligible patients will be screened for partici-
pation in the study by a member of the direct care team
with eligibility confirmed by a delegated clinical co-
investigator. Data used for calculating the CDAI and
faecal calprotectin results must have been collected no
greater than 4 weeks before the screening visit. Once an
eligible patient has consented to study participation
(consent being obtained in writing by a research nurse),
their contact details will be forwarded to the research
assistant, who will contact the participant to book them
in for their baseline assessment, which must be per-
formed within 4 weeks from when the screening assess-
ments have been fully completed.
Randomisation and allocation concealment
Following collection of all baseline measurements, par-
ticipants will be randomly assigned 1:1:1 to HIIT, MICT
or usual care control. Randomisation will be achieved
using a computer-generated randomisation schedule
stratified by centre and baseline disease status (inactive
[CDAI <150] vs. mildly active [CDAI 150–219]) using
permuted blocks of random sizes. The block sizes and
allocation sequence will not be disclosed to ensure con-
cealment. A statistician at York Trials Unit will manage
the randomisation process. The intervention facilitator
(research assistant) will request email notification of a
participant’s treatment allocation after baseline assess-
ments have been completed. They will then inform the
participant of their allocation (i.e. participants will not
be blinded to the treatment allocation).
Blinding
Blinding of trial participants and the intervention facili-
tator is not possible. Questionnaires will be completed
by the participants independently and checked by a
researcher for completeness. Anthropometric, cardiore-
spiratory fitness and disease activity outcomes will be
assessed by researchers blinded to group allocation.
Participants will be asked not to disclose their allocation
to the technician.
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Statistical analysis
A detailed analysis plan will be prepared and agreed with
the Trial Management Group and Trial Steering Com-
mittee, before all of the data has been collected. Analyses
will be conducted in STATA (StataCorp, 2013) using the
principles of intention-to-treat. The flow of participants
through each stage of the trial will be presented in a
CONSORT diagram. Descriptive statistics will be used
to characterise the groups at baseline and to present the
feasibility outcomes. Although determining differences
in clinical outcomes between the three arms is not the
primary purpose of this trial, comparisons will be under-
taken to investigate the feasibility of studying these out-
comes and to calculate estimates for the likely effect
sizes and 95% confidence intervals. As recommended in
guidelines for good practice for the analysis of pilot
studies [23], the focus of the results will be on the
estimates of the treatment effects rather than statistical
significance and as such no hypothesis testing will be
undertaken. Differences between the two comparison
groups will be presented in the form of an unadjusted
mean difference for continuous outcomes, and an odds
ratio for binary outcomes, with their associated 95%
confidence intervals.
Criteria for success
This feasibility trial will be deemed successful and lead
to the development of a proposal for an adequately
powered randomised controlled trial if:
1. At least one of the exercise programmes is shown to
be acceptable, based on a combination of data from
participant interviews, the number and type of adverse
events in each group and exercise session adherence
Fig. 1 Schematic diagram of recruitment and assessment
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rates (at least 67% of participants completing at least 24
of the 36 sessions).
2. At least 24 patients are recruited during the
12-month recruitment window (based on recruitment
from three NHS Hospital Trusts and 1–2 recruits per
site per two months).
3. At least 67% of participants provide valid
cardiorespiratory fitness, disease activity (CDAI) and
quality of life (IBDQ) data at the 13-week follow-up visit.
The criteria for success will provide the basis for inter-
preting the results of this study and determine whether
it is appropriate to proceed to a full trial and if any mod-
ifications need to occur for a full trial to be feasible.
Ethical and safety considerations
The research study will follow the Health Research
Authority’s processes for gaining NHS permissions and
approvals. We are confident that the assessment proce-
dures and exercise programmes will be safe. Exercise
testing has been demonstrated to be safe for patients
with CD [30] and other chronic diseases [31, 32]. Never-
theless, patients’ suitability for the study will be assessed
by a clinical co-investigator, and participants will be
closely monitored during all training and testing ses-
sions. Furthermore, exercise sessions will be supervised
by experienced staff who are trained in resuscitation.
Exercise training will be discontinued if a clinical co-
investigator deems it necessary (e.g. if a patient experi-
ences a disease relapse) or if the participant withdraws
consent. The trial will also be subject to oversight from
an independent Trial Steering Committee.
Safety reporting
Adverse event reporting will be conducted in accordance
with the Sponsor’s Adverse Event Reporting Procedures.
A clinical co-investigator will be responsible for deter-
mining the causality and seriousness of adverse events
and ensuring that appropriate action is taken. Informa-
tion about adverse events will be collected from the
beginning of any study-related procedure (i.e. when writ-
ten consent has been obtained). The adverse event
reporting period will stop at the participant’s final trial
contact, i.e. at the 26-week follow-up.
We will record all serious adverse events, as well as all
non-serious adverse events that are either deemed to be
related to participation in the research or result in with-
drawal from an exercise programme or the study. Ser-
ious adverse events are defined as any untoward medical
occurrence that falls in one of the following criteria:
results in death; is life threatening; requires unplanned
or prolonged hospitalisation; results in persistent or
significant disability or incapacity; or results in a con-
genital abnormality or birth defect. Non-serious events
are defined as untoward medical occurrences that do
not fulfil any of the serious adverse event criteria.
Data management
Paper case report forms will be used to collect study
outcome data. An exercise session case report form will
also be completed for each exercise session for partici-
pants in the two exercise intervention groups. Examples
of the case report forms will be stored in the Trial
Master File. Each centre’s personnel will receive training
from members of the Trial Management Group in the
study requirements, including how to complete the case
report forms, how to conduct the assessments (e.g.
cardiopulmonary exercise tests, blood sampling) and
how to deliver the interventions. The study case report
forms will be stored in participant files, which in turn
will be stored in numerical order in a secure, restricted
access location. The Chief Investigator (LB) and Trial
Manager (GT) will regularly review case report forms to
ensure that they are being completed appropriately, and
they will conduct a site monitoring visit once a site has
recruited three participants.
Data on paper case report forms will be manually
entered into customised spreadsheets in Microsoft Excel.
Entered data will be double-checked by a second re-
searcher. Once completed, these spreadsheets will be
password encrypted and then transferred electronically
to the statistician at York Trials Unit using the Univer-
sity of York’s secure document DropOff Service. Data
validation plans will be implemented by the statistician
to identify data points that do not fall within an ex-
pected range of values. Following data cleaning, the data
will be summarised and analysed according to the statis-
tical analysis plan.
Essential trial documentation (i.e. the documents
which individually and collectively permit evaluation of
the conduct of a clinical trial and the quality of the data
produced) will be kept with the Trial Master File and In-
vestigator Site Files. The Sponsor will ensure that this
documentation will be retained for a minimum of 5 years
after the conclusion of the trial to comply with standards
of Good Clinical Practice. Case report forms will be
stored for a minimum of 5 years after the conclusion of
the trial as paper records and a minimum of 20 years in
electronic format. All paper records will be stored in a
secure storage facility or off-site by the University of
Hertfordshire. All electronic records will be stored on a
password-protected server.
Dissemination
The dissemination strategy for this research will be to
inform a wide range of local, national and international
audiences about the results and conclusions. It must,
however, be remembered as part of this strategy that the
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current project is preliminary work aimed at informing a
subsequent definitive clinical trial.
Health professionals—we aim to publish our research
in journals that cover the relevant medical specialties
and with preference for those that deposit publications
in open access databases to increase free dissemination.
In addition, we aim to present this research at appropri-
ate national and international conferences.
Users—from this perspective, we aim in the first in-
stance to collaborate with our patient representatives
and local experts in the patient and public involvement
to best facilitate user dissemination. We plan to write a
specific news piece that will be forwarded to appropriate
groups and organisations.
Service managers—as an exploratory study, it is un-
likely that results from this study will directly influence
commissioning processes in the short term. Moreover,
we will engage with appropriate primary and secondary
care groups to discuss support for our proposed defini-
tive study leading on from this research.
Discussion
Regular physical exercise may benefit several aspects of
physical and mental health in people with inflammatory
bowel disease; however, the evidence base is sparse. The
EXACT study is a rigorously designed randomised con-
trolled feasibility trial that will provide useful prelimin-
ary information about the acceptability and effectiveness
of two common modes of supervised exercise training
(high-intensity interval training and moderate-intensity
continuous training) in people with inactive or mildly
active Crohn’s disease. The findings will inform the de-
velopment of a future adequately powered, multi-centre,
randomised controlled trial.
Trial status
Recruitment started in April 2016 and is ongoing.
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